Search results
Showing 76 to 90 of 134 results for atrial fibrillation
Evidence-based recommendations on CorVue (Abbott Medical), HeartInsight (Biotronik), HeartLogic (Boston Scientific) and TriageHF (Medtronic) for algorithm-based remote monitoring in people with cardiac implantable electronic devices
Hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea (IPG598)
Evidence-based recommendations on hypoglossal nerve stimulation for moderate to severe obstructive sleep apnoea in adults. This involves implanting a device under the skin in the chest and connecting it to a nerve under the tongue (hypoglossal nerve).
Discontinued [GID-TAG377]
Discontinued [GID-TAG383]
(older children) - inhaler devices 13 February 2002 TA249 Atrial fibrillation - dabigatran etexilate 7 February 2012 TA098 Attention...
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treating and preventing deep vein thrombosis and pulmonary embolism in adults.
subclinical hyperthyroidism is associated with an increased risk of atrial fibrillation, osteoporosis, dementia, and death, including...
Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]
Discontinued [GID-TAG416]
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
people with atrial fibrillation: - Which automated blood pressure monitors are suitable for people with hypertension and atrial...
Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.
Photodynamic therapy for early-stage oesophageal cancer (IPG200)
Evidence-based recommendations on photodynamic therapy for early-stage oesophageal cancer. This involves injecting a photosensitising agent into the tumour which is then activated by a light to destroy the tumour cells.
View recommendations for IPG200Show all sections
Sections for IPG200
preventing stroke and systemic embolism in people with non-valvular atrial fibrillation Number TA275 Date issued February 2013
Dapagliflozin for treating chronic heart failure with reduced ejection fraction (TA679)
Evidence-based recommendations on dapagliflozin (Forxiga) for symptomatic chronic heart failure with reduced ejection fraction in adults.
Evidence-based recommendations on personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. This involves opening the chest through the breastbone and wrapping a mesh around the outside of the aorta at the part closest to the heart.
View recommendations for IPG724Show all sections